Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
RCUS

Arcus Biosciences Inc

RCUS

15.76USD+0.12 (+0.77%)Market Closed
Watchlist

Market Summary

USD15.76+0.12
Market Closed
0.77%

RCUS Alerts

  • Losses in recent quarter

RCUS Stock Price

View Fullscreen

RCUS RSI Chart

RCUS Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-4.02

Price/Sales (Trailing)

9.86

EV/EBITDA

-3.53

Price/Free Cashflow

-3.85

RCUS Price/Sales (Trailing)

RCUS Profitability

EBT Margin

-241.16%

Return on Equity

-56.4%

Return on Assets

-24.62%

Free Cashflow Yield

-25.97%

RCUS Fundamentals

RCUS Revenue

Revenue (TTM)

119.5M

Revenue Y/Y

-4.71%

Revenue Q/Q

10.34%

RCUS Earnings

Earnings (TTM)

-293.3M

Earnings Y/Y

-9.37%

Earnings Q/Q

5.33%

Price Action

Last 7 days

-1.9%

Last 30 days

-1.6%

Last 90 days

-26.3%

Trailing 12 Months

-49.2%

How does RCUS drawdown profile look like?

RCUS Financial Health

Current Ratio

4.41

RCUS Investor Care

Shares Dilution (1Y)

3.38%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023119.1M121.1M119.5M0
2022391.5M409.1M433.2M112.1M
202185.7M93.4M38.4M383.0M
202015.0M15.0M77.8M78.0M
20198.9M9.4M6.8M15.0M
20182.7M3.9M8.0M8.4M
20170001.4M

Latest Insider Trading transactions for RCUS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 01, 2023
azoy alexander
sold
-4,215
14.95
-282
chief accounting officer
Sep 22, 2023
jarrett jennifer
sold
-427,166
19.99
-21,369
chief operating officer
Sep 18, 2023
nuyten dimitry sa
back to issuer
-75,643
20.4
-3,708
chief medical officer
Sep 18, 2023
jarrett jennifer
back to issuer
-255,122
20.4
-12,506
chief operating officer
Jul 28, 2023
jarrett jennifer
sold
-911,250
20.25
-45,000
chief operating officer
Jul 03, 2023
azoy alexander
sold
-20,777
20.41
-1,018
chief accounting officer
Jun 28, 2023
gilead sciences, inc.
bought
19,452,600
19.26
1,010,000
-
Jun 22, 2023
jarrett jennifer
sold
-237,795
19.12
-12,437
chief operating officer
Jun 16, 2023
tang carolyn c.
back to issuer
-55,960
19.35
-2,892
general counsel
Jun 16, 2023
jaen juan c.
back to issuer
-93,267
19.35
-4,820
president

1–10 of 50

Which funds bought or sold RCUS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 07, 2023
Hudson Bay Capital Management LP
added
39.13
536,350
2,872,000
0.01%
Dec 06, 2023
CITIGROUP INC
added
20.79
165,515
2,615,840
-%
Dec 04, 2023
TUCKER ASSET MANAGEMENT LLC
sold off
-100
-1,016
-
-%
Nov 29, 2023
Decheng Capital Management III (Cayman), LLC
unchanged
-
-2,052,700
15,612,700
4.99%
Nov 24, 2023
DEUTSCHE BANK AG\
added
14.4
5,272
482,029
-%
Nov 22, 2023
KBC Group NV
unchanged
-
-
82,000
-%
Nov 22, 2023
Public Sector Pension Investment Board
reduced
-29.04
-707,463
1,190,120
0.01%
Nov 21, 2023
Walleye Trading LLC
reduced
-54.4
-924,068
623,798
-%
Nov 21, 2023
COMERICA BANK
added
2,827
441,965
441,965
-%
Nov 21, 2023
Walleye Capital LLC
added
4.51
-251,882
3,047,800
0.01%

1–10 of 36

Latest Funds Activity

Are funds buying RCUS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RCUS
No. of Funds

Schedule 13G FIlings of Arcus Biosciences Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 06, 2023
gilead sciences, inc.
35%
25,586,953
SC 13D/A
Feb 14, 2023
biotechnology value fund l p
1.7%
1,236,002
SC 13G/A
Feb 14, 2023
pfm health sciences, lp
3.7%
6
SC 13G/A
Feb 09, 2023
vanguard group inc
6.04%
4,373,177
SC 13G
Jan 26, 2023
blackrock inc.
13.0%
9,389,048
SC 13G/A
Jan 20, 2023
blackrock inc.
13.0%
9,389,048
SC 13G/A
Oct 17, 2022
pfm health sciences, lp
5.5%
6
SC 13G
May 09, 2022
blackrock inc.
11.1%
7,967,677
SC 13G
Mar 14, 2022
biotechnology value fund l p
3.0%
2,156,510
SC 13G
Feb 14, 2022
ecor1 capital, llc
7.9%
5,523,358
SC 13G/A

Recent SEC filings of Arcus Biosciences Inc

View All Filings
Date Filed Form Type Document
Dec 05, 2023
4
Insider Trading
Nov 07, 2023
8-K
Current Report
Nov 07, 2023
10-Q
Quarterly Report
Sep 26, 2023
4
Insider Trading
Sep 22, 2023
144
Notice of Insider Sale Intent
Sep 20, 2023
4
Insider Trading
Sep 20, 2023
4
Insider Trading
Sep 15, 2023
144
Notice of Insider Sale Intent
Sep 15, 2023
144
Notice of Insider Sale Intent

RCUS Fair Value

Loading...

Peers (Alternatives to Arcus Biosciences Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
31.5B
-
6.13% 411799.31%
-3.7K
218.4K
- -102.45%
30.6B
10.7B
12.59% -56.51%
-8.83
2.87
-53.67% -129.46%
21.3B
1.7B
0.38% -28.56%
-41.84
12.38
79.37% 56.87%
17.5B
2.3B
8.71% -10.95%
119.09
7.58
15.05% 75.21%
12.3B
3.6B
1.18% -34.97%
28.84
3.4
8.35% -51.49%
MID-CAP
7.4B
272.9M
33.62% 24.68%
-12.26
27.23
141.38% 4.43%
5.7B
-
10.65% 240.88%
-9.69
48.33
54.84% -12.96%
3.4B
631.9M
-9.53% 43.40%
-23.12
5.44
23.54% 31.53%
3.3B
223.4M
14.00% -9.85%
-16.45
14.86
- -26.24%
2.6B
240.7M
-11.63% -24.14%
-12.52
10.67
-1.03% -16.59%
SMALL-CAP
1.5B
348.4M
12.92% -15.71%
24.33
4.33
81.69% -7.29%
661.3M
1.0B
-18.09% -67.84%
-1.2
0.63
-43.15% 58.48%
100.5M
6.4M
- -79.35%
-0.61
15.6
-44.11% 50.48%
37.6M
-
385.71% 119.35%
-0.58
-
- -29.23%
23.7M
-
40.31% 4064.72%
-0.5
-
- -13.74%

Arcus Biosciences Inc News

Latest updates
Knox Daily08 Dec 202301:27 pm38 hours ago
InvestorIdeas.com05 Dec 202307:15 pm4 days ago
Nasdaq04 Dec 202312:08 pm5 days ago
Defense World01 Dec 202310:06 am8 days ago
Yahoo Finance27 Nov 202308:00 am12 days ago
MarketBeat27 Nov 202308:00 am12 days ago
Knox Daily16 Nov 202308:00 am23 days ago
Yahoo Finance12 Nov 202308:00 am27 days ago
IANS India Pvt Ltd09 Nov 202312:18 am31 days ago
Yahoo Finance08 Nov 202308:00 am31 days ago
Yahoo Finance06 Nov 202308:00 am33 days ago
Zonebourse.com06 Nov 202308:00 am33 days ago
Seeking Alpha01 Nov 202307:00 am38 days ago
Nasdaq26 Oct 202307:00 am44 days ago
Yahoo Finance23 Oct 202307:00 am47 days ago

Financials for Arcus Biosciences Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue10.3%32,000,00029,000,00025,000,00033,537,00033,581,00027,000,00018,000,000354,617,0009,461,0009,461,0009,461,0009,970,00064,530,0001,750,0001,750,0009,750,0001,750,0001,750,0001,750,0001,562,0004,291,000
Operating Expenses0%112,000,000112,000,000111,000,000108,059,000102,978,00096,000,00085,000,00073,598,00087,597,00085,597,00082,208,00061,499,00062,978,00047,125,00030,150,00027,277,00024,999,00030,910,00020,523,00015,046,00016,436,000
  S&GA Expenses7.1%30,000,00028,000,00030,000,00027,801,00026,294,00026,000,00024,000,00023,010,00016,343,00016,826,00015,821,00013,383,00011,177,00011,432,0007,008,0006,590,5007,758,0005,911,0004,969,0003,610,0003,577,000
  R&D Expenses-2.4%82,000,00084,000,00081,000,00080,258,00076,684,00070,000,00061,000,00050,588,00071,254,00068,771,00066,387,00048,364,00051,801,00035,693,00023,142,00020,686,50017,241,00024,999,00015,554,00011,436,00012,859,000
EBITDA Margin-3.0%-2.36-2.29-2.27-2.320.210.18-0.720.15-7.76-3.16-1.41-1.54-1.05-5.43-5.43------
Income Taxes100.0%2,000,0001,000,0002,000,000-2,000--1,000,0002,000,000-------------
Earnings Before Taxes6.8%-69,000,000-74,000,000-78,000,000-67,270,500-64,919,000-67,000,000-67,000,000281,538,000-77,975,000-75,970,000-72,593,000----------
EBT Margin-2.8%-2.41-2.35-2.33-2.370.190.17-0.730.14-7.85-3.20-1.44-1.58-1.09-5.65-5.65------
Net Income5.3%-71,000,000-75,000,000-80,000,000-67,268,500-64,919,000-67,000,000-68,000,000279,538,000-77,975,000-75,970,000-72,593,000-51,853,0001,822,000-45,074,000-27,753,000-16,598,000-22,352,000-28,090,000-17,670,000-12,295,000-10,812,000
Net Income Margin-3.5%-2.45-2.37-2.34-2.380.180.160.150.14-7.35-2.14-1.97-1.58-1.13-7.45-6.32------
Free Cashflow-17.7%-73,000,000-62,000,000-101,000,000-70,119,000-82,277,000-66,817,000651,213,000-70,609,000-61,615,000-80,068,000-69,957,000-51,399,000215,194,000-24,194,000-31,486,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-2.4%1,1911,2201,2541,3451,3941,4771,5431,592839899935772811481176203217239259275287
  Current Assets-10.5%8829861,0151,0671,1011,2271,2641,262545746842736797472166193200228245259265
    Cash Equivalents-20.0%18423023820621827354914817932039017322228567.0058.0079.0076.0068.0071.0075.00
  Net PPE11.1%50.0045.0037.0035.0034.0033.0033.0032.0029.0024.0015.0011.009.008.009.009.0010.0010.0011.0011.0012.00
Liabilities-----69572974775029729427027026753.0036.0039.0040.0042.0037.0040.0042.00
  Current Liabilities11.1%20018017919317716416116614313013212216340.0021.0023.0021.0027.0019.0017.0017.00
Shareholder's Equity-8.1%520566600657699747797842543605665502544429141164177197222235245
  Retained Earnings-10.2%-768-697-622-542-474-409-343-275-554-476-400-328-276-278-233-205-188-166-138-122-110
  Additional Paid-In Capital-----1,1831,1651,1451,1181,0971,0811,066830821707373369366363360358356
Shares Outstanding0.4%75.0075.0073.0073.0072.0072.0071.0071.0070.0070.0067.0065.0063.0049.0044.0046.0044.0044.0044.0035.0043.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-10.5%-63,000-57,000-98,000-69,739-81,261-65,000654,000-61,932-53,757-73,995-66,316-50,050216,265-23,938-31,277-9,471-27,399-19,753-16,839-7,107-11,765
  Share Based Compensation0%18,00018,00019,00016,52216,47815,00017,00014,28714,58513,36712,7618,0666,0024,4703,4622,4372,7402,1301,6741,0541,048
Cashflow From Investing-57.7%11,00026,000129,00046,81123,189-215,000-268,00018,782-88,6113,00362,826136-387,119-87,07340,056-12,10430,36426,67314,2792,511-83,337
Cashflow From Financing-73.9%6,00023,0001,00011,1952,8054,00015,00011,3311,3182,231222,1202,002107,518328,870610520-41.00649-5.00771-7.00

RCUS Income Statement

2023-09-30
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Total revenues$ 32,000,000$ 33,000,000$ 86,000,000$ 78,000,000
Operating expenses:    
Research and development (Net of recoveries of $22, $27, $89 and $93 from a related party)82,000,00077,000,000247,000,000208,000,000
General and administrative30,000,00026,000,00088,000,00076,000,000
Total operating expenses112,000,000103,000,000335,000,000284,000,000
Loss from operations(80,000,000)(70,000,000)(249,000,000)(206,000,000)
Non-operating income (expense):    
Interest and other income, net12,000,0005,000,00030,000,0008,000,000
Effective interest on liability for sale of future royalties(1,000,000)0(2,000,000)(1,000,000)
Total non-operating income, net11,000,0005,000,00028,000,0007,000,000
Loss before income taxes(69,000,000)(65,000,000)(221,000,000)(199,000,000)
Income tax expense(2,000,000)0(5,000,000)(1,000,000)
Net loss$ (71,000,000)$ (65,000,000)$ (226,000,000)$ (200,000,000)
Net loss per share, basic (in dollars per share)$ (0.94)$ (0.90)$ (3.07)$ (2.78)
Net loss per share, diluted (in dollars per share)$ (0.94)$ (0.90)$ (3.07)$ (2.78)
Shares used to compute net loss per share, basic (in shares)74.672.273.671.8
Shares used to compute net loss per share, diluted (in shares)74.672.273.671.8
License and Development Services Revenue    
Revenues:    
Total revenues$ 22,000,000$ 23,000,000$ 58,000,000$ 48,000,000
Other Collaboration Revenue    
Revenues:    
Total revenues$ 10,000,000$ 10,000,000$ 28,000,000$ 30,000,000

RCUS Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 184$ 206
Marketable securities615803
Receivable from collaboration partners ($22 and $39 from a related party)5239
Prepaid expenses and other current assets3119
Total current assets8821,067
Long-term marketable securities151129
Property and equipment, net5035
Other noncurrent assets ($6 and $2 from a related party)108114
Total assets1,1911,345
Current liabilities:  
Accounts payable1720
Deferred revenue ($96 and $97 to a related party)10397
Other current liabilities8076
Total current liabilities200193
Deferred revenue, noncurrent ($309 and $355 to a related party)326355
Other noncurrent liabilities145140
Commitments
Stockholders’ equity:  
Preferred stock, $0.0001 par value per share; 10.0 shares authorized; no shares issued and outstanding.00
Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 74.8 shares in 2023 and 72.9 shares in 2022 issued and outstanding1,2911,206
Accumulated deficit(768)(542)
Accumulated other comprehensive loss(3)(7)
Total stockholders’ equity520657
Total liabilities and stockholders’ equity$ 1,191$ 1,345
RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
 CEO
 WEBSITEwww.arcusbio.com
 EMPLOYEES500

Arcus Biosciences Inc Frequently Asked Questions


What is the ticker symbol for Arcus Biosciences Inc? What does RCUS stand for in stocks?

RCUS is the stock ticker symbol of Arcus Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcus Biosciences Inc (RCUS)?

As of Fri Dec 08 2023, market cap of Arcus Biosciences Inc is 1.18 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RCUS stock?

You can check RCUS's fair value in chart. The fair value of Arcus Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcus Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RCUS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcus Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether RCUS is over valued or under valued. Whether Arcus Biosciences Inc is cheap or expensive depends on the assumptions which impact Arcus Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RCUS.

What is Arcus Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, RCUS's PE ratio (Price to Earnings) is -4.02 and Price to Sales (PS) ratio is 9.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RCUS PE ratio will change depending on the future growth rate expectations of investors.